Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving the efficiency of induction motor drive by flux and torque control: A hybrid LSE-RERNN approach.

ISA transactions·2024
Same author

Benthic foraminifera as an environmental proxy for pollutants along the coast of Chennai, India.

Chemosphere·2022
Same author

Large magnetoresistance and quantum oscillations in Sn<sub>0.05</sub>Pb<sub>0.95</sub>Te.

Journal of physics. Condensed matter : an Institute of Physics journal·2021
Same author

Contrasting the Surface Phonon Dispersion of Pb_{0.7}Sn_{0.3}Se in Its Topologically Trivial and Nontrivial Phases.

Physical review letters·2019
Same author

Gd<sub>2</sub>Te<sub>3</sub>: an antiferromagnetic semimetal.

Journal of physics. Condensed matter : an Institute of Physics journal·2019
Same author

Long-term effects of allergen-specific subcutaneous immunotherapy for house dust mite induced allergic rhinitis.

The Journal of laryngology and otology·2018

Related Experiment Video

Updated: Jul 5, 2026

Electrophoretic Delivery of &#x3B3;-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Galanin and epilepsy.

J T Lerner1, R Sankar, A M Mazarati

  • 1Dept. of Pediatrics, Neurology Division, D. Geffen School of Medicine at the University of California, Los Angeles, BOX 951752, 22-474 MDCC, Los Angeles, California 90095-1752, USA.

Cellular and Molecular Life Sciences : CMLS
|May 27, 2008
PubMed
Summary

Galanin peptide demonstrates significant anticonvulsant properties, effectively reducing seizure activity in animal models. This peptide shows promise for developing novel galanin-based antiepileptic drugs.

More Related Videos

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
09:29

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy

Published on: August 17, 2021

Related Experiment Videos

Last Updated: Jul 5, 2026

Electrophoretic Delivery of &#x3B3;-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
09:29

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy

Published on: August 17, 2021

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Galanin's neuroanatomical distribution and physiological roles suggest involvement in seizure regulation.
  • Evidence indicates galanin influences the initiation and spread of epileptic activity.

Purpose of the Study:

  • To investigate the role of galanin and its receptors in epilepsy.
  • To evaluate the potential of galanin-based therapies for epilepsy treatment.

Main Methods:

  • Administration of galanin receptor agonists and antagonists in animal models of epilepsy.
  • Genetic manipulation (gene deletion and overexpression) of galanin and its receptors in transgenic mice.
  • Utilizing virus vector transfection to modulate galanin levels in seizure pathways.

Main Results:

  • Galanin receptor agonists attenuated seizure responses in animal models.
  • Blocking galanin receptors resulted in proconvulsant effects.
  • Genetic deletion of galanin or its type 1 receptor led to spontaneous seizures or increased seizure susceptibility.
  • Overexpression of galanin inhibited seizure progression.
  • Galanin exerts anticonvulsant effects via both type 1 and type 2 receptors.

Conclusions:

  • Galanin possesses significant anticonvulsant properties mediated through its receptors.
  • Synthetic galanin receptor agonists show potential for systemic administration and development as novel antiepileptic drugs.